<?xml version='1.0' encoding='utf-8'?>
<document id="8540752"><sentence text="In vitro and in vivo enhancement of ddI activity against Rauscher murine leukemia virus by ribavirin."><entity charOffset="91-100" id="DDI-PubMed.8540752.s1.e0" text="ribavirin" /></sentence><sentence text="Ribavirin has been reported to enhance the activity of ddI against HIV"><entity charOffset="0-9" id="DDI-PubMed.8540752.s2.e0" text="Ribavirin" /></sentence><sentence text=" We explored this enhancement of antiviral activity in Rauscher murine leukemia virus (RMuLV) models in vitro and in vivo" /><sentence text=" The significant finding in these studies was that combinations of the drugs exhibited virus titer reductions that were greater than would be expected if the drug interactions were simply additive" /><sentence text=" These effects were designated synergistic by the method of Prichard and Shipman (Prichard, M" /><sentence text="N" /><sentence text=" and Shipman, C" /><sentence text=", Jr" /><sentence text=" (1990)" /><sentence text=" A three-dimensional model to analyze drug-drug interaction, Antiviral Res" /><sentence text=" 14, 181-206)" /><sentence text=" In addition to the antiviral synergy, we also observed some synergistic toxicity in the animal model" /><sentence text="" /></document>